Tg Therapeutics earnings were $23.4M for the trailing 12 months ending Dec 31, 2024, with 77.8% growth year over year. The latest TGTX earnings report on Dec 31, 2024 announced Q4 2024 earnings of $23.3M, up 501.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TGTX reported annual earnings of $23.4M, with 84.5% growth.
TGTX past earnings growth
How has TGTX's earnings growth performed historically?
What were Tg Therapeutics's earnings last quarter?
On TGTX's earnings call on Invalid Date, Tg Therapeutics (NASDAQ: TGTX) reported Q4 2024 earnings per share (EPS) of $0.16, up 260% year over year. Total TGTX earnings for the quarter were $23.33 million. In the same quarter last year, Tg Therapeutics's earnings per share (EPS) was -$0.10.
As of the last Tg Therapeutics earnings report, Tg Therapeutics is currently profitable. Tg Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $23.38 million, a 84.52% increase year over year.
What was TGTX's earnings growth in the past year?
As of Tg Therapeutics's earnings date in Invalid Date, Tg Therapeutics's earnings has grown 77.78% year over year. This is 65.64 percentage points higher than the US Biotechnology industry earnings growth rate of 12.14%. TGTX earnings in the past year totalled $23.38 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.